Boston Scientific (BSX) Price Target Cut to $64 by Truist
Published on Β· Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowTruist has decreased its price target for Boston Scientific Corp. (BSX) from $85 to $64 while maintaining a Buy rating. This revision comes after management indicated slowing growth in the U.S. market for the Watchman device. Goldman Sachs also cut its target price for BSX from $81 to $71, while still offering a Buy rating, noting expected revenue growth of at least 7% and a double-digit increase in EPS. The adjustments reflect analysts' concerns over the product's performance but confidence in BSX's broader financial profile.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Boston Scientific Corporation (BSX)
Boston Scientific makes medical devices for cardiology and other specialties.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier BSX news
- Boston Scientific (BSX) Price Target Cut by Jefferies on Growth Outlook
- Boston Scientific Reports Clinical Trials Driving Growth in Cardiology Market
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
Related News
Boeing (BA) Posts Better-Than-Expected Free Cash Flow in Recent Report
Oct 27
Natera Technology Featured in 25 Abstracts at ESMO Congress
Oct 27
Amazon (AMZN) Retail Earnings Lower Than AWS Revenue Highlights
Oct 27
Celestica, Cadence, Rambus Beat Q3 Estimates, Raising AI Future Questions
Oct 27